Biophytis

98 articles with Biophytis

• Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program

  3/17/2023

  Biophytis SA annouces that it will change the ratio of its American Depositary Shares to Biophytis ordinary shares from one ADS representing 10 Shares, to one ADS representing 100 Shares.

• Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference

  3/9/2023

  Biophytis SA announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th and the 12th of March 2023.

• Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19

  3/2/2023

  Biophytis SA announced that it has signed a master service agreement with the pharmaceutical company Intsel Chimos, which will become its Pharmaceutical Operator/Exploitant in France for Sarconeos in the context of the early access program application, requested for the treatment of severe forms of COVID-19, if approved.

• Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19

  2/27/2023

  Biophytis SA, announced that it has begun the process of early access application in France from the French National Authority for Health for the treatment of severe COVID-19 with Sarconeos.

• Biophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023

  2/23/2023

  Biophytis SA announced it is convening an Extraordinary and Ordinary Shareholders' Meeting for March 30, 2023.

• Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

  2/2/2023

  Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, released the final results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.

• Biophytis Publishes its Financial Results for the First Half of 2022

  1/31/2023

  Biophytis SA publishes its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021.

• Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

  1/12/2023

  Biophytis SA received a deficiency notice from The Nasdaq Stock Market, Inc. stating that the Company has not filed its financial information for the six-month period ended June 30, 2022 on a Form 6-K and as a result the Company no longer complies with Nasdaq's listing rules for continued listing set forth in the Listing Rule 5250.

• Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed

  1/5/2023

  Biophytis SA announces its participation at the 41st JP Morgan Healthcare Conference, which will be held in San Francisco from the 9th to 12th of January 2023, and at the Invest Securities Biomed Event which will be held on the 24th of January 2023 in Paris.

• Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19

  11/3/2022

  Biophytis SA released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.

• Biophytis Publishes Its Key Financial Figures As at 30 June 2022, Announces a Restatement of the Financial Statements Published As of December 31st, 2021 and Provides an Update on the Operational Milestones

  10/31/2022

  Biophytis SA publishes its key financial figures as of 30 June 2022 and announces that the audited consolidated financial statements previously published by the Company for the year ended December 31st, 2021 are being restated to correct the accounting treatment of the Kréos financing agreement signed in November 2021.

• Biophytis Announces Receipt of Nasdaq Notice - October 26, 2022

  10/26/2022

  Biophytis SA announced that it has received written notification from the Nasdaq Stock Market LLC dated October 20, 2022, indicationg that, based upon a closing bid price of less than $1.00 per share for the Company's American Depositary Shares for the prior 30 consecutive business deay period, the Company no longer satisfies Nasdaq Listing Rule 5550.

• Biophytis Participates in H.C. Wainwright 24th Annual Global Investment Conference

  9/15/2022

  Biophytis SA made a presentation to investors on the 12th of September in New York, on the occasion of the 24th Global Investment Conference organised by the HC Wainwright bank, which is being held from 12 to 14 September 2022 in New York.

• Biophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related Respiratory Failure

  9/7/2022

  Biophytis SA released top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.

• Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million

  6/30/2022

  Biophytis SA announces the issuance of the 160 Bonds Redeemable in Cash and New and Existing Shares for a total amount of €4 million under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York for €32 million.

• Biophytis Presents the Development of Sarconeos (BIO101) in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD International Congress

  6/27/2022

  Biophytis SA announced that it is giving an oral presentation on the development of Sarconeos for the treatment of sarcopenia at the 15th International SCWD Congress.

• Biophytis: Results of the Combined General Meeting on June 21, 2022

  6/22/2022

  Biophytis SA announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting.

• Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a Rare Neuromuscular Disease

  6/16/2022

  Biophytis SA announced that it is presenting new preclinical efficacy data for its product Sarconeos in SMA at the SMA Cure 2022 conference in Anaheim, California, USA on June 16-19, 2022.

• Biophytis: Biophytis Announces its Participation at the BIO International Convention in San Diego from the 13th to the 16th of June 2022

  5/12/2022

  Biophytis SA announces it will participate, represented by its CEO Stanislas Veillet and its Business Development Director Benoit Canolle, at the Biotechnology Innovation Organization International Convention to be held in San Diego from the 13th to the 16th of June 2022, alongside thousands of world leaders in biotechnology and the pharmaceutical industry.

• Biophytis: Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022

  4/19/2022

  Biophytis SA announces it will present and discuss the results of Sarconeos development program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research to be held virtually and on site in Boston from April 20 to April 22, 2022.